Latest Pharma Insights
Executives On The Move: Three New CEOs And Five New CMOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Vyome Holdings, CoRegen and Resolution Therapeutics, plus Takeda hires Rhonda Pacheco from Eli Lilly as the President of its US unit.
Scrip - September 18, 2025
Recent moves in the industry include changes at the top at Vyome Holdings, CoRegen and Resolution Therapeutics, plus Takeda hires Rhonda Pacheco from Eli Lilly as the President of its US unit.
Scrip - September 18, 2025
Wellnex Life Plots New Zealand Expansion With New Partner
Australian CHC player Wellnex signs up Storelink to take more of its brands to consumers in New Zealand.
HBW Insight - September 18, 2025
Australian CHC player Wellnex signs up Storelink to take more of its brands to consumers in New Zealand.
HBW Insight - September 18, 2025
EADV: Leo Makes A Big Leap With Eczema Drug Temtokibart Set For Phase III
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
Scrip - September 18, 2025
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
Scrip - September 18, 2025
Indapamide Breaks The Scale With A 1,000%+ UK Rise In August
A massive 1,115% average price increase was seen for indapamide 2.5mg tablets in the UK in August.
Generics Bulletin - September 18, 2025
A massive 1,115% average price increase was seen for indapamide 2.5mg tablets in the UK in August.
Generics Bulletin - September 18, 2025
Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside
Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.
Scrip - September 18, 2025
Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.
Scrip - September 18, 2025
Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
Scrip - September 18, 2025
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
Scrip - September 18, 2025
Biocon Adds To A Crowded Field For US Denosumab
Biocon Biologics has celebrated US FDA approval for its biosimilar rivals to Prolia and Xgeva. But how will the firm fare in such a competitive market?
Generics Bulletin - September 18, 2025
Biocon Biologics has celebrated US FDA approval for its biosimilar rivals to Prolia and Xgeva. But how will the firm fare in such a competitive market?
Generics Bulletin - September 18, 2025
French Specialist Horus Takes More European Rights To Formycon’s Eylea Biosimilar
Formycon has signed a further licensing deal in Europe, this time for its Eylea biosimilar that holds a pan-European marketing authorization.
Generics Bulletin - September 18, 2025
Formycon has signed a further licensing deal in Europe, this time for its Eylea biosimilar that holds a pan-European marketing authorization.
Generics Bulletin - September 18, 2025
Have Your Say On EU Digital Regulation Overkill
European Commission is expected to have tsunami of responses, including from medtech stakeholders to its public consultation. The US is already intensely interested in developments.
Medtech Insight - September 18, 2025
European Commission is expected to have tsunami of responses, including from medtech stakeholders to its public consultation. The US is already intensely interested in developments.
Medtech Insight - September 18, 2025
The Story Behind Maxwellia’s UK Naproxen Pain Relief Switch
In an exclusive Q&A, HBW Insight catches up with Maxwellia CEO Anna Maxwell to find out more about the UK Rx-to-OTC switch of Naprosyn Pain Relief, the first new OTC?single-ingredient oral analgesic for acute back, muscle and joint pain in over a decade.
HBW Insight - September 18, 2025
In an exclusive Q&A, HBW Insight catches up with Maxwellia CEO Anna Maxwell to find out more about the UK Rx-to-OTC switch of Naprosyn Pain Relief, the first new OTC?single-ingredient oral analgesic for acute back, muscle and joint pain in over a decade.
HBW Insight - September 18, 2025
Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
Scrip - September 18, 2025
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
Scrip - September 18, 2025
NAD’s ‘Vision For The Future’: Influencer Training, Private Equity Claims Assessment
The National Advertising Division’s VP Phyllis Hurwitz Marcus and Head of Policy Mary Engle discuss the “vision for the future," during NAD's 2025 Annual Conference in DC Sept. 16-17.
HBW Insight - September 18, 2025
The National Advertising Division’s VP Phyllis Hurwitz Marcus and Head of Policy Mary Engle discuss the “vision for the future," during NAD's 2025 Annual Conference in DC Sept. 16-17.
HBW Insight - September 18, 2025
Executives On The Move: Three New CEOs And Five New CMOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Vyome Holdings, CoRegen and Resolution Therapeutics, plus Takeda hires Rhonda Pacheco from Eli Lilly as the President of its US unit.
Scrip - September 18, 2025
Recent moves in the industry include changes at the top at Vyome Holdings, CoRegen and Resolution Therapeutics, plus Takeda hires Rhonda Pacheco from Eli Lilly as the President of its US unit.
Scrip - September 18, 2025
EADV: Leo Makes A Big Leap With Eczema Drug Temtokibart Set For Phase III
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
Scrip - September 18, 2025
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
Scrip - September 18, 2025
Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside
Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.
Scrip - September 18, 2025
Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.
Scrip - September 18, 2025
Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
Scrip - September 18, 2025
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
Scrip - September 18, 2025
Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
Scrip - September 18, 2025
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
Scrip - September 18, 2025
Have Your Say On EU Digital Regulation Overkill
European Commission is expected to have tsunami of responses, including from medtech stakeholders to its public consultation. The US is already intensely interested in developments.
Medtech Insight - September 18, 2025
European Commission is expected to have tsunami of responses, including from medtech stakeholders to its public consultation. The US is already intensely interested in developments.
Medtech Insight - September 18, 2025
Wellnex Life Plots New Zealand Expansion With New Partner
Australian CHC player Wellnex signs up Storelink to take more of its brands to consumers in New Zealand.
HBW Insight - September 18, 2025
Australian CHC player Wellnex signs up Storelink to take more of its brands to consumers in New Zealand.
HBW Insight - September 18, 2025
The Story Behind Maxwellia’s UK Naproxen Pain Relief Switch
In an exclusive Q&A, HBW Insight catches up with Maxwellia CEO Anna Maxwell to find out more about the UK Rx-to-OTC switch of Naprosyn Pain Relief, the first new OTC?single-ingredient oral analgesic for acute back, muscle and joint pain in over a decade.
HBW Insight - September 18, 2025
In an exclusive Q&A, HBW Insight catches up with Maxwellia CEO Anna Maxwell to find out more about the UK Rx-to-OTC switch of Naprosyn Pain Relief, the first new OTC?single-ingredient oral analgesic for acute back, muscle and joint pain in over a decade.
HBW Insight - September 18, 2025
NAD’s ‘Vision For The Future’: Influencer Training, Private Equity Claims Assessment
The National Advertising Division’s VP Phyllis Hurwitz Marcus and Head of Policy Mary Engle discuss the “vision for the future," during NAD's 2025 Annual Conference in DC Sept. 16-17.
HBW Insight - September 18, 2025
The National Advertising Division’s VP Phyllis Hurwitz Marcus and Head of Policy Mary Engle discuss the “vision for the future," during NAD's 2025 Annual Conference in DC Sept. 16-17.
HBW Insight - September 18, 2025
Indapamide Breaks The Scale With A 1,000%+ UK Rise In August
A massive 1,115% average price increase was seen for indapamide 2.5mg tablets in the UK in August.
Generics Bulletin - September 18, 2025
A massive 1,115% average price increase was seen for indapamide 2.5mg tablets in the UK in August.
Generics Bulletin - September 18, 2025
Biocon Adds To A Crowded Field For US Denosumab
Biocon Biologics has celebrated US FDA approval for its biosimilar rivals to Prolia and Xgeva. But how will the firm fare in such a competitive market?
Generics Bulletin - September 18, 2025
Biocon Biologics has celebrated US FDA approval for its biosimilar rivals to Prolia and Xgeva. But how will the firm fare in such a competitive market?
Generics Bulletin - September 18, 2025
French Specialist Horus Takes More European Rights To Formycon’s Eylea Biosimilar
Formycon has signed a further licensing deal in Europe, this time for its Eylea biosimilar that holds a pan-European marketing authorization.
Generics Bulletin - September 18, 2025
Formycon has signed a further licensing deal in Europe, this time for its Eylea biosimilar that holds a pan-European marketing authorization.
Generics Bulletin - September 18, 2025
The Rise In China Deals: How International Biopharma Is Turning To China For Innovation
The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.
In Vivo - September 17, 2025
The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.
In Vivo - September 17, 2025
Deals In Depth: August 2025
Seven $1bn+ alliances were penned in August, and two exceeded $2bn.
In Vivo - September 17, 2025
Seven $1bn+ alliances were penned in August, and two exceeded $2bn.
In Vivo - September 17, 2025
As Pricing Pressures Mount, Biopharma Turns To AI To Reduce Trial Failure Rates
With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.
In Vivo - September 17, 2025
With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.
In Vivo - September 17, 2025
Can Kennedy’s Crackdown Really Dismantle Big Pharma’s Ad Machine?
For months, US Health and Human Services Secretary Robert F. Kennedy Jr. had talked about banning direct-to-consumer television ads for prescription drugs. And now, he is making good on his promise – but in a roundabout way.
In Vivo - September 17, 2025
For months, US Health and Human Services Secretary Robert F. Kennedy Jr. had talked about banning direct-to-consumer television ads for prescription drugs. And now, he is making good on his promise – but in a roundabout way.
In Vivo - September 17, 2025